Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.
TidsskriftArthritis Research & Therapy
Udgave nummer4
Sider (fra-til)1-11
StatusUdgivet - 24 jul. 2009

ID: 18339138